About Citrate synthase-lysine N-methyltransferase CSKMT, mitochondrial
Citrate synthase-lysine N-methyltransferase CSKMT, mitochondrial (CSKMT) is a protein
from Homo sapiens identified by UniProt accession
A8MUP2, 240 residues long.
MolForge cross-references it against 0 known binders and
22 disease associations.
Target properties
| Protein name | Citrate synthase-lysine N-methyltransferase CSKMT, mitochondrial |
| UniProt accession | A8MUP2 |
| Gene | CSKMT |
| Organism | Homo sapiens |
| Length | 240 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (22)
Diseases linked to this target (Open Targets).
- mean corpuscular hemoglobin concentration · score 0.20
- resting heart rate · score 0.19
- body fat percentage · score 0.15
- blood protein measurement · score 0.15
- low density lipoprotein triglyceride measurement · score 0.10
- high density lipoprotein cholesterol measurement · score 0.10
- aspartate aminotransferase measurement · score 0.10
- serum alanine aminotransferase measurement · score 0.10
- sex hormone-binding globulin measurement · score 0.10
- triglyceride measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A8MUP2-F1 | alphafold | PREDICTED | 87.65 | — |
Amino-acid sequence (240 residues)
MAALRRMLHL PSLMMGTCRP FAGSLADSCL ADRCLWDRLH AQPRLGTVPT FDWFFGYDEV QGLLLPLLQE AQAASPLRVL DVGCGTSSLC TGLYTKSPHP VDVLGVDFSP VAVAHMNSLL EGGPGQTPLC PGHPASSLHF MHADAQNLGA VASSGSFQLL LDKGTWDAVA RGGLPRAYQL LSECLRVLNP QGTLIQFSDE DPDVRLPCLE QGSYGWTVTV QELGPFRGIT YFAYLIQGSH
Explore Citrate synthase-lysine N-methyltransferase CSKMT, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets